The United Laboratories International Holdings Limited announced that on 1 September 2023, the application for the clinical trial of class 1 innovative new drug UBT251 Injection self-developed by The United Bio-Technology (Hengqin) Co. Ltd., a wholly-owned subsidiary of the Company, on indication of overweight or obesity was approved by China National Medical Products Administration, with reference number of CXHL2300699. At present, the Company is the first enterprise in China and the second enterprise in the world to be approved for the clinical trials of a long-acting triple agonist of GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide)/GCG (glucagon) prepared by chemical synthetic polypeptide.

The indication on adult type 2 diabetes has been approved for clinical trial on 29 August 2023, and the clinical application for the indication of nonalcoholic fatty liver/nonalcoholic steatohepatitis ("NASH") is in the final review stage. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.